BioCentury
ARTICLE | Clinical News

Aubagio teriflunomide: Additional Phase III data

October 22, 2012 7:00 AM UTC

Additional data from the double-blind, international Phase III TOWER trial in 1,169 patients with relapsing MS showed that once-daily 7 and 14 mg oral Aubagio each significantly increased the proportion of patients who were relapse-free vs. placebo. Specifically, 55% of patients receiving low-dose Aubagio (p=0.0016) and 52% of patients receiving high-dose Aubagio (p<0.0001) were relapse-free vs. 38% for placebo. Data were presented at the European Committee for Treatment and Research in Multiple Sclerosis meeting in Lyon. ...